Stryker Co. (NYSE:SYK) Stake Reduced by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 26.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,198 shares of the medical technology company's stock after selling 5,928 shares during the period. Prime Capital Investment Advisors LLC's holdings in Stryker were worth $5,852,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Savvy Advisors Inc. boosted its stake in Stryker by 29.7% in the 3rd quarter. Savvy Advisors Inc. now owns 1,388 shares of the medical technology company's stock worth $501,000 after purchasing an additional 318 shares during the period. Ashton Thomas Private Wealth LLC raised its stake in Stryker by 3.3% during the third quarter. Ashton Thomas Private Wealth LLC now owns 14,610 shares of the medical technology company's stock valued at $5,278,000 after purchasing an additional 464 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Stryker by 2.9% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,143,573 shares of the medical technology company's stock worth $413,127,000 after acquiring an additional 32,491 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Stryker during the 3rd quarter valued at $362,000. Finally, Waverton Investment Management Ltd lifted its holdings in shares of Stryker by 5.5% in the 3rd quarter. Waverton Investment Management Ltd now owns 1,242 shares of the medical technology company's stock worth $449,000 after acquiring an additional 65 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In related news, insider Viju Menon sold 600 shares of the firm's stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Viju Menon sold 600 shares of the company's stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares in the company, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 67,381 shares of company stock valued at $24,825,275. Company insiders own 5.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wells Fargo & Company upped their target price on shares of Stryker from $381.00 to $405.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. Stifel Nicolaus decreased their price objective on shares of Stryker from $375.00 to $365.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. UBS Group upped their target price on Stryker from $366.00 to $370.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. Needham & Company LLC upped their price target on shares of Stryker from $393.00 to $409.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Finally, Royal Bank of Canada boosted their target price on shares of Stryker from $386.00 to $400.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and a consensus target price of $393.65.

Stryker Price Performance

NYSE:SYK traded up $1.23 during mid-day trading on Wednesday, hitting $388.34. 1,678,243 shares of the company's stock traded hands, compared to its average volume of 1,256,902. Stryker Co. has a 1 year low of $282.35 and a 1 year high of $390.59. The company has a market cap of $148.04 billion, a PE ratio of 41.62, a price-to-earnings-growth ratio of 2.92 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm's 50 day simple moving average is $362.38 and its 200 day simple moving average is $346.42.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the firm posted $2.46 earnings per share. The company's quarterly revenue was up 11.9% compared to the same quarter last year. Sell-side analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.